BC
URGN icon

Birchview Capital’s UroGen Pharma URGN Stock Holding History

Birchview Capital’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607K Buy
+16,487
New +$447K 0.28% 49

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Birchview Capital's URGN Position: Q2 2026 in Review

Birchview Capital opened a new position in UroGen Pharma (URGN) in Q2 2026: 16,487 shares worth $607K. The stake represents 0.28% of the portfolio and ranks #49 among its holdings.

189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Birchview Capital held 16,487 shares of UroGen Pharma worth $607K as of Q2 2026.
  • UroGen Pharma was a new Birchview Capital position in Q2 2026.
  • UroGen Pharma made up 0.28% of Birchview Capital's portfolio in Q2 2026, its #49 holding.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.